AZTA
Azenta, Inc.
AZTA's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over AZTA overall, supported by stronger fundamentals and lower modeled downside.
AZTA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Stable | |
| Strong |
AZTA's revenue and balance sheet are currently healthy, and its cash flow is stable, but its profitability is weak.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AZTA PE Valuation
AZTA has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AZTA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for AZTA, with profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over AZTA on the outlook, with more favorable profitability expectations.
AZTA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.55 | — |
| Q3 2026 | -$3.62 | -$2.41 |
AZTA lost $3.62 per share over the past year, a bigger loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over AZTA in the latest year-over-year earnings comparison.
AZTA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $167.1M | +5% |
| Q2 2026 | $161.2M | +12% |
| Q1 2026 | $144.8M | +1% |
| Q4 2025 | $148.6M | +0.8% |
AZTA's revenue has grown year over year every quarter since late 2025: $167M last quarter, up 5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2.6% | -2.1 points |
| Q1 2026 | -115% | -103 points |
| Q4 2025 | -4.9% | +2.8 points |
| Q3 2025 | 1.2% | N/A |
| Q2 2025 | -0.5% | N/A |
| Q1 2025 | -11% | N/A |
| Q4 2024 | -7.7% | N/A |
AZTA's operating margin was −2.6% last quarter, down 2.1 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over AZTA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over AZTA on profitability, with a higher operating margin.
AZTA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$5.2M | -135% |
| Q1 2026 | $6.1M | -13% |
| Q4 2025 | $14.7M | -34% |
LLY has the edge over AZTA in the latest year-over-year cash flow comparison.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over AZTA in the latest year-over-year cash flow comparison.
AZTA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.7% | -777K shares |
| 1 year | -1.2% | -537K shares |
AZTA has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AZTA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -9.7x | Net Cash |
| Q3 2025 | -8.0x | Net Cash |
| Q2 2025 | -9.0x | Net Cash |
| Q1 2025 | -10.6x | Net Cash |
AZTA has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
AZTA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.0 | Neutral |
| Stochastic | 64.2 | Neutral |
AZTA's weekly RSI is 69 (neutral) and its Stochastic is 64 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AZTA PE vs Healthcare Sector
| Metric | AZTA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AZTA has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AZTA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $37.9 | 16% above |
| 20 week MA | $33.4 | 31% above |
| 50 week MA | $29.8 | 47% above |
| 100 week MA | $32.5 | 35% above |
| 200 week MA | $42.0 | 4.5% above |
AZTA has climbed back above all five of its weekly moving averages, and it's now 4.5% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
AZTA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $42.1 | $74.6 | +77% |
| 2021 | $74.6 | $101.0 | +35% |
| 2022 | $101.0 | $58.5 | -42% |
| 2023 | $58.5 | $65.1 | +11% |
| 2024 | $65.1 | $51.3 | -21% |
| 2025 | $51.3 | $34.8 | -32% |
| 2026 YTD | $34.8 | $43.9 | +26% |
AZTA has finished lower in three of the last six years. It's up 26% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over AZTA on returns for 2026, with the stronger performance.